RXST Stock Overview
A commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RxSight, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.04 |
| 52 Week High | US$66.54 |
| 52 Week Low | US$20.66 |
| Beta | 1.21 |
| 11 Month Change | -2.45% |
| 3 Month Change | 11.32% |
| 1 Year Change | 101.41% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 256.50% |
Recent News & Updates
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09Recent updates
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12RxSight: First And Only Customizable Intraocular Lens
Aug 26Shareholder Returns
| RXST | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.5% | -1.2% | 0.7% |
| 1Y | 101.4% | -2.5% | 21.5% |
Return vs Industry: RXST exceeded the US Medical Equipment industry which returned -2.6% over the past year.
Return vs Market: RXST exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| RXST volatility | |
|---|---|
| RXST Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RXST has not had significant price volatility in the past 3 months.
Volatility Over Time: RXST's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 374 | Ron Kurtz | www.rxsight.com |
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power.
RxSight, Inc. Fundamentals Summary
| RXST fundamental statistics | |
|---|---|
| Market cap | US$2.21b |
| Earnings (TTM) | -US$44.50m |
| Revenue (TTM) | US$101.10m |
22.0x
P/S Ratio-50.0x
P/E RatioIs RXST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXST income statement (TTM) | |
|---|---|
| Revenue | US$101.10m |
| Cost of Revenue | US$37.02m |
| Gross Profit | US$64.08m |
| Other Expenses | US$108.58m |
| Earnings | -US$44.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 63.39% |
| Net Profit Margin | -44.01% |
| Debt/Equity Ratio | 0% |
How did RXST perform over the long term?
See historical performance and comparison